Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes.
OBJECTIVE
Collaboration with patients with rheumatoid arthritis (RA) highlights that outcomes important to them include fatigue, coping, and life enjoyment. However, these are not commonly measured in clinical trials. There is little evidence about which outcomes patients would prioritize, or what factors influence patients' prioritization. Our objective was to develop a complementary core set with patients to promote inclusion of their priority outcomes in pharmacologic interventions.


METHODS
Nominal groups were conducted with RA patients to rank 63 outcomes generated from previous in-depth interviews. A multicenter postal survey provided the final selection of core outcomes for the Rheumatoid Arthritis Patient Priorities for Pharmacologic Interventions (RAPP-PI), in which RA patients rated the importance of the priority outcomes from the nominal groups and ranked the top 6.


RESULTS
Twenty-six patients participated in 5 nominal group discussions and reduced the 63 initial outcomes to the 32 most important. A total of 254 participants in the survey ranked priority treatment outcomes to form the RAPP-PI: pain, activities of daily living, joint damage, mobility, life enjoyment, independence, fatigue, and valued activities. The 8 priorities represent 3 domains of treatment outcomes: direct impact of RA, psychosocial well-being, and function/participation. Chi-square tests showed that disease severity, disease duration, sex, and patients' perceptions of managing, self-efficacy, and normality influenced the selection of priority treatment outcomes.


CONCLUSIONS
Collaboration with patients has captured their perspectives of priority outcomes from pharmacologic interventions. Although there is some overlap with professional core outcomes, the additional use of this complementary set will give a broader evaluation of effectiveness of interventions from the key stakeholders: patients.
Sanderson
T
T
University of West of England and Bristol Royal Infirmary, Bristol, UK. Tessa2.Sanderson@uwe.ac.uk
Morris
M
M
Calnan
M
M
Richards
P
P
Hewlett
S
S
D000203:Activities of Daily Living; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000523:psychology; D001294:Attitude to Health; D017281:Cost of Illness; D017144:Focus Groups; D006801:Humans; D017060:Patient Satisfaction; D011788:Quality of Life; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D018501:Antirheumatic Agents
J Rheumatol. 2008 Apr;35(4):603-9
18322993
Musculoskeletal Care. 2005;3(3):131-42
17042002
J Rheumatol. 1997 Jul;24(7):1370-7
9228139
BMJ. 2001 May 19;322(7296):1240-3
11358783
Disabil Rehabil. 2001 Nov 10;23(16):706-21
11732560
Rheumatology (Oxford). 2001 Nov;40(11):1221-30
11709605
Ann Rheum Dis. 2009 Nov;68(11):1680-5
19054825
Ann Rheum Dis. 2009 Feb;68(2):183-90
18375533
BMJ. 2001 Jun 2;322(7298):1357-60
11387189
J Rheumatol. 1993 Mar;20(3):579-81
8478878
Arthritis Care Res (Hoboken). 2010 May;62(5):640-6
20461785
Ann Rheum Dis. 2006 Jun;65(6):763-9
16249225
Musculoskeletal Care. 2004;2(2):101-12
17041974
Arthritis Rheum. 1980 Feb;23(2):137-45
7362664
J Rheumatol. 2007 May;34(5):1174-7
17477482
Rheumatology (Oxford). 2004 Aug;43(8):1034-8
15150436
Musculoskeletal Care. 2004;2(1):40-50
17041967
BMJ. 1995 Aug 5;311(7001):376-80
7640549
Arthritis Res Ther. 2006;8(4):R84
16684371
Trials. 2007 Nov 26;8:38
18039364
Ann Rheum Dis. 2002 Nov;61(11):986-93
12379521
Arthritis Rheum. 1988 Mar;31(3):315-24
3358796
Arthritis Rheum. 1993 Jun;36(6):729-40
8507213
J Rheumatol. 2003 Apr;30(4):880-3
12672221
Arthritis Rheum. 1980 Feb;23(2):146-52
7362665
Rheumatology (Oxford). 2005 Jan;44(1):105-10
15381792
Ann Rheum Dis. 2007 Nov;66(11):1485-90
17472993
Arthritis Rheum. 2001 Aug;45(4):372-7
11501725
J Rehabil Med. 2004 Jul;(44 Suppl):87-93
15370754
Arthritis Rheum. 2002 Aug;47(4):391-7
12209485